Compare KEY & STE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KEY | STE |
|---|---|---|
| Founded | 1825 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.6B | 25.9B |
| IPO Year | N/A | 1992 |
| Metric | KEY | STE |
|---|---|---|
| Price | $20.49 | $254.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 9 |
| Target Price | $20.25 | ★ $268.25 |
| AVG Volume (30 Days) | ★ 17.9M | 619.9K |
| Earning Date | 01-20-2026 | 11-05-2025 |
| Dividend Yield | ★ 3.97% | 1.00% |
| EPS Growth | ★ 34785.88 | 59.39 |
| EPS | 0.86 | ★ 6.97 |
| Revenue | ★ $5,934,000,000.00 | $5,702,415,000.00 |
| Revenue This Year | $77.19 | $9.61 |
| Revenue Next Year | $6.55 | $6.23 |
| P/E Ratio | ★ $23.89 | $36.12 |
| Revenue Growth | ★ 22.30 | 7.08 |
| 52 Week Low | $12.73 | $200.98 |
| 52 Week High | $20.84 | $268.60 |
| Indicator | KEY | STE |
|---|---|---|
| Relative Strength Index (RSI) | 75.76 | 45.89 |
| Support Level | $18.26 | $249.92 |
| Resistance Level | $19.73 | $261.45 |
| Average True Range (ATR) | 0.43 | 4.93 |
| MACD | 0.23 | -1.76 |
| Stochastic Oscillator | 87.37 | 22.75 |
With assets of around $185 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.